Immunome IMNM
NASDAQ IMNM
$20.89 -0.62 (-2.88%)
As of: Oct 1, 2026 · 3:59 PM EDT

Immunome (IMNM) Preferred Stock Liabilities (2019 - 2020)

Updated

Immunome's Preferred Stock Liabilities came in at $48.37 million for Q3 2020, up 75.8% from $27.51 million a year earlier and unchanged from the prior quarter.

Analysis

Immunome (IMNM) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends

At the end of FY2019, Immunome's Preferred Stock Liabilities was $38.89 million.

  • The five-year range for quarterly Preferred Stock Liabilities is $27.51 million (Q3 2019) to $48.39 million (Q2 2020).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Immunome 2.44 Bn 410.39 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2020 48.37 Mn
Jun 30, 2020 48.39 Mn
Dec 31, 2019 38.89 Mn
Sep 30, 2019 27.51 Mn
API Access

Immunome Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=IMNM&period=max&api_key=YOUR_API_KEY